Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study

Fig. 2

Pathological complete response (pCR) in the intention-to-treat population according to magnetic resonance imaging (MRI) response and treatment assignment. Total pCR (tpCR, ypT0/isN0) and breast pCR (bpCR, ypT0/is) in the intention-to-treat population (N = 129), stratified by MRI response and treatment: Cohort A (MRI responders treated with docetaxel, carboplatin, and trastuzumab), Cohort B (MRI non-responders treated with docetaxel, carboplatin, and trastuzumab), and Cohort C (MRI non-responders treated with docetaxel, carboplatin, trastuzumab, and pyrotinib). The number (n) of patients who achieved pCR in a subgroup (N) are presented. The pCR rates were calculated with a 95% confidence interval (CI)

Back to article page